Commentary

Video

Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

Author(s):

Lia Gore, MD,Sarah K. Tasian, MD

Fact checked by:

Chris Ryan

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
Relapsed/Refractory LBCL | Image credit: © Om.Nom.Nom - stock.adobe.com
June 13th 2025

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
March 26th 2025

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

IDH1-Mutated AML | Image Credit: © Motion Pics - stock.adobe.com
June 13th 2025

Olutasidenib Maintenance Generates Durable RFS in IDH1-Mutated AML Following Induction CR/CRi

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Iptacopan in paroxysmal nocturnal hemoglobinuria: © Bipul Kumar - stock.adobe.com
June 13th 2025

Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria

Cyclosporin Plus Cyclophosphamide in GVHD: © TheWaterMeloonProjec - stock.adobe.com
June 13th 2025

Cyclosporin Plus Cyclophosphamide Outperforms SOC Therapy in GVHD Prevention